| Aptorum Group is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic assets to treat diseases particularly in oncology and infectious diseases. In addition, Co. is also pursuing therapeutic projects in neurology, gastroenterology, metabolic disorders, women's health and other disease areas. Co.'s Lead Projects are: ALS-4, which is a small molecule for the treatment of bacterial infections; SACT-1, which is a repurposed drug for the treatment of neuroblastoma; and rapid pathogen identification and detection diagnostics, which is a molecular-based rapid pathogen identification and detection diagnostics technology. The APM average annual return since 2018 is shown above.
The Average Annual Return on the APM average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether APM average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the APM average annual return calculation with any dividends reinvested as applicable (on ex-dates).